Opdivo
Manufacturing · United States · <25 Employees
View Company Info for Free
About
Headquarters
United StatesWebsite
www.opdivo.comRevenue
<$5 MillionIndustry
Who is Opdivo
Learn about OPDIVO® (nivolumab), a prescription medicine that treats certain types of cancers. Find the information you need to care for your OPDIVO® and OPDIVO + YERVOY® (ipilimumab) patients. Please see Indication and Important Safety Information.Explore more
Opdivo Org Chart
Is Opdivo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Opdivo had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Opdivo
Product Launch: Get notified when Opdivo launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Opdivo, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Opdivo recently announced quarterly report
Funding: Get notified immidiatlly once Opdivo has new funding data
Check if Opdivo has recently received funding, and reach out quickly before it becomes old news!
Check out if Opdivo is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Opdivo as Masked Content
Find 3 more new buyers
Compare Similar Companies to Opdivo
Compare insights from companies similar to Opdivo, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Opdivo
<$5M
-
Opdivo Employee Growth Rate
View Opdivo’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Opdivo Tech Stack
A closer look at the technologies used by Opdivo
Most Recent Scoops
Last Week
Hot Scoop - Business
Last month
Hot Scoop - Financial
Last month
Hot Scoop - Opportunities
Opdivo News & Media
OPDIVO (Nivolumab) Drug Pipeline Research Report 2024: The First-in-human Immunoglobulin G4 (IgG4) PD-1 Immune Checkpoint Inhibitor Antibody - Market Size, Forecast, and Emerging Insights 2019-2032 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "OPDIVO Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets. A detailed picture of the OPDIVO for ovarian cancer in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has expanded CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx as an aid in identifying esophageal squamous cell carcinoma patients for treatment with Bristol Myers Squibb’s PD-1-targeted immunotherapeutic OPDIVO® (nivolumab), in combination with fluoropyrimidine and platinum-based chemotherapy or OPDIVO® in combination with YERVOY® (ipilimumab). These combined treatments provide new hBristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #MEDIA--BMS Receives Positive CHMP Opinion for Opdivo as Adjuvant Treatment for Esophageal or Gastro Junction Cancer Patients w/ RPD Following ChemoUbiVac Announces Clinical Trial Collaboration with Bristol Myers Squibb on Combination Immunotherapy for Advanced Triple Negative Breast Cancer
PORTLAND, Ore.--(BUSINESS WIRE)--UbiVac, Inc. (www.ubivac.com) today announced it has entered into a clinical trial collaboration with Bristol Myers Squibb (NYSE:BMY) to evaluate the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product, DPV-001™, a first-in-class cancer vaccine that exploits autophagy, in combination with Bristol Myers Squibb’s anti-OX40 (BMS-986178) combined with sequenced administration of the programmed death-1 (PD-1) immune checkpoint inhibitorBristol-Myers Squibb Reports Second Quarter Financial Results
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Reports Second Quarter Financial Results
Read more news
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Opdivo
Learn about OPDIVO® (nivolumab), a prescription medicine that treats certain types of cancers. Find the information you need to care for your OPDIVO® and OPDIVO + YERVOY® (ipilimumab) patients. Please see Indication and Important Safety Information.... Read More
